MAPT and Alzheimer disease: This supported our hypothesis that plasma P‐tau217 reflects both Aβ and tau accumulation in AD, but primarily reflects Aβ accumulation during the early disease stages (when tau PET is still negative) and primarily tau accumulation during the later disease stages (when both Aβ and tau PET are positive).